fashion -WSS

fashion

author：comprehensive 2025-09-02 09:41:31 - browse：59

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： What causes osteoarthritis? Researchers study link to brain protein

focus

WSS

Microsoft launches AI tool for clinical documentation through Epic

Flu vaccine reformulation won't be easy, manufacturers warn

Cardiologists urge adding sexual orientation, gender identity to health records

Body of missing toddler recovered in Delaware River days after flood: Police

There's an unseen cost to disruptive road

Microsoft launches AI tool for clinical documentation through Epic

focus

fashion

focus

Wildfire smoke exposes gaps in outdoor worker protections

Mass General, Mayo Clinic look to monetize custom

Moonlake's readout produced a cash windfall. Risks remain

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

Walensky prepares to leave CDC — and Congress — behind

Caitlin Bernard's story shows physicians can't shy from advocacy

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Prior authorization reform is both possible and imperative

Hepatitis C has a cure — but many Americans still lack access to it

What causes osteoarthritis? Researchers study link to brain protein

explore

New rules on organ donation and transplantation 'will bring chaos'

Cardiologists urge adding sexual orientation, gender identity to health records

Marvel Studios reveals new trailer for 'The Marvels': Watch here

HPV vaccine, cervical cancer study delivers historic results

HIPAA doesn't protect reproductive records from prosecutors

FDA endorses new sterilization method for medical devices

focus

leisure time

focus

leisure time